You are here: Home >>About Us >>What We Do
What We Do
We license innovative molecules from pharmaceutical and biotechnology companies and develop them for patients in China, South Korea and beyond.
Our first program is FTC001 is an IL17A mAb licensed from Janssen Biotech Inc. for use China, Taiwan and South Korea.This asset is ready for Phase1/2 studies in psoriasis.
Globally, psoriasis (PsO) has a prevalence of ~2%, but varies widely with genetic background. Caucasian and Scandinavian populations see rates up to 11%. (J. Investig. Dermatol. 2013, 133, 377–385.)

In Asia, prevalence of psoriasis in
·China is 0.11- 0.47% (Ran Pan, Jianzhong Zhang 2014)
·Korea 0.45% (Jin Yong Lee et al 2017)
·Taiwan 0.24% (Hsien-Yi Chiu et al 2018).

Psoriatic Arthritis (PSA) in
·China is 0.02% (95% CI 0%, 0.07%) (Ru L et al 2011)
·Korea 14.1% of PsO (Hyo Jin Choi et al 2008)
·Taiwan 12.7% of PsO (Ting-Shun Wang et al 2016).

Prevalence of ankylosing spondylitis (AS) in
·China  is 0.3% ~ 0.5%, indicating there could be more than 4 million people with AS in China (J. Y. Jin, Zhonghua Nei Ke Za Zhi, vol. 49, pp. 832–835, 201; S. C. Ng, Seminars in Arthritis and Rheumatism, vol. 37, no. 1, pp. 39–47, 2007. );
·Korea 0.052% (Jin-Sung Park et al 2018).
·Taiwan54,857 AS patients were documented  (Hsieh, M.-Y., & Kuo, C.-F. 2016).